To enhance the ability of ADV to modulate antitumor immune responses, efforts have focused primarily on remodeling the tumor immune microenvironment by using ADVs as vectors to express genes encoding costimulatory molecules, cytokines, chemokines, and tumor-associated antigens [52, 53]. This evidence concerns the gene CD276 and neoplasm.